Banque Transatlantique SA Acquires New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Banque Transatlantique SA bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,600 shares of the biopharmaceutical company's stock, valued at approximately $1,133,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Avalon Trust Co acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $36,000. Finally, Private Wealth Management Group LLC increased its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 39 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $12.34 on Friday, hitting $535.33. The company had a trading volume of 721,583 shares, compared to its average volume of 763,469. The firm has a 50 day moving average of $616.03 and a two-hundred day moving average of $699.76. The stock has a market capitalization of $58.52 billion, a price-to-earnings ratio of 13.98, a PEG ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $9.55 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.66%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Analyst Upgrades and Downgrades

A number of research firms have commented on REGN. Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. Finally, TD Cowen lowered their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $892.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.